TUNÇ ÖNEŞ, Sabahat İNANIR, Ahmet TOPRAK, FUAT DEDE, T. Yusuf ERDİL, Feyza ŞEN, H. Turgut TUROĞLU

Myokardiyal perfüzyon SPECT görüntülemede dipiridamol stres EKG bulgularının klinik önemi

Amaç: Bu çalışmada koroner anjiyografi sonuçları “Altın standart” olarak kabul edilerek, dipiridamol infüzyonu sırasında ve sonrasında EKG’de izlenen anlamlı ST segment depresyonunun klinik önemi araştırıldı. Gereç ve Yöntemler: Bu çalışmaya 5 yıllık bir dönem içinde bölümümüze MPS ile değerlendirilmesi için refere edilen ve bu tetkik sırasında dipiridamol ile farmakolojik stres uygulanan hastalar alındı. Değerlendirme kriterlerine uygun olduğu saptanan toplam 76 olguya dipiridamol infüzyonu standart bir protokol ile uygulandı. Dipiridamol infüzyonu sırasında ve takibinde olguların EKG bulguları, kalp atım hızı ve kan basıncı değerleri kayıt altına alındı. Bulgular: Diagnostik koroner anjiyografi bulguları pozitif olarak değerlendirilen 60 hastanın 23’ünde (%38) IV dipiridamol infüzyonu sonrası 1 mm ST segment depresyonu gelişti. Dipiridamol infüzyonu sonrası anlamlı ST segment depresyonu 3 damar hastası olan olgularda daha sık izlenmiştir. Dipiridamol infüzyonu sırasında ve sonrasında EKG’de izlenen ST segment depresyonu için sensitivite, spesifite, pozitif ve negatif öngörü değerleri sırasıyla %38, %81, %89 ve %26 olarak bulundu. Hipertansiyonun eşlik ettiği sol ventriküler hipertrofi varlığında ise spesifite değeri daha düşük bulunmuştur (%50). Sonuç: Dipiridamol infüzyonu sonrası oluşan ST segment depresyonu koroner arter hastalığı için sensitif olmasa da spesifik bir belirteçtir. Literatürdeki araştırmalar ışığında, dipiridamol ile farmakolojik stres sonrası anlamlı ST depresyonu izlenen ancak MPS sonucu normal raporlanan olgular yakın klinik takibe alınmalı ve bu olgu grubunda klinik gereklilik halinde ek diagnostik testlerden (koroner anjiyografi gibi) kaçınılmamalıdır.

The clinical importance of dipyridamole stress ECG findings in myocardial perfusion SPECT imaging

Objective: The results of the coronary angiography were accepted as a “Gold Standard” in this study and the clinical importance of significant ST-segment depression on the ECG during and after dipyridamole infusion was evaluated. Material and Methods: During a 5-year period, the patients who were referred for evaluation with MPS and underwent dipyridamole pharmacological stress were included in this study. Total 76 patients who fullfilled the evaluation criteria, underwent dipyridamole infusion according to a standard protocol. The cardiac rhythm was monitored continuously and ECG findings, heart rate and blood pressure were recorded during and after dipyridamole infusion. Results: Of 60 patients with a diagnostic positive coronary angiography, 23 (38%) developed 1 mm ST-segment depression after IV dipyridamole. Dipyridamole induced ST-segment depression occured more frequently in patients with three-vessel coronary artery disease. Sensitivity, specifity, positive predictive and negative predictive values for ST-segment depression on the ECG during and after dipyridamole infusion were 38%, 81%, 89% and 26% respectively. The specificity value was found lower in patients with left ventricular hypertrophy secondary to hypertension (50%). Conclusion: Although the ST-segment depression occuring after dipyridamole infusion is not sensitive for coronary artery disease, it is a specific marker. In the light of the research in the literature, close clinical follow-up and further diagnostic testing (ie, coronary angiography) should not be avoided in case of clinical necessity with normal MPS associated with significant ST-segment depression in patients undergoing dipyridamole pharmacologic stress testing.

PDF

___

1. Botvinick EH, Dae MW: Dipyridamole perfusion scintigraphy. Sem Nuc Med 1991;3:242- 6531. Nishimura S, Mahmarian JJ, Boyce TM, Verani MS: Quantitative thallium-201 single-photon emission computed tomography during maximal pharmacologic coronary vasodilation with adenosine for assessing coronary artery disease. J Am Coll Cardiol 1991;18:736-45.
2. Datz FL, Gullberg G, Gabor FV, Morton KA: SPECT myocardial perfusion imaging update. Sem US CT MRI 1991;12:28-44.
3. Hendel RC, Whitfield SS, Villegas BJ, Cutler BS, Leppo JA: Prediction of late cardiac events by dipyridamole thallium imaging in patients undergoing elective vascular surgery. Am J Cardiol 1992;70:1243-9.
4. Ignaszewski AP, McCormick LX, Heslip PG, McEvan AJ, Humen DP: Safety and clinical utility of combined intravenous dipyridamole/ symptom-limited exercise stress test with coronary artery disease. J Nucl Med 1993;34:2053-61.
5. Leppo JA: Dipyridamole-Thallium imaging: The lazy man’s stress test. J Nucl Med 1989;30:281-7.
6. McLaughlin DP, Beller GA, Linden J, Ayers CR, RipleyML, Taylor H, et all: Hemodynamic and metabolic corralates of dipyridamole-induced myocardial thallium-201 perfusion abnormalities in multivessel coronary artery disease. Am J Cardiol 1994;74:1159-64.
7. Stratmann HG, Tamesis BR, Younis LT, Wittry MD, Miller DD: Prognostic value of dipyridamole technetium-99m sestamibi myocardial tomography in patints with stable chest pain who are unable to exercise. Am J Cardiol 1994;73:647-52.
8. Verzijlbergen JF, Vermeersch PH, Laarman GJ, Ascoop C: Inadequate exercise leads to suboptimal imaging. Thallium-201 myocardial imaging after dipyridamole combined with low level exercise unmasks ischemia in symptomatic patients with nondiagnostic Tl-201 scans who exercise submaximally. J Nucl Med;1991;32:2071-8.
9. Leppo J, Boucher CA, Okada RD, Newell JB, Strauss HW, Pohost GM: Serial thallium-201 myocardial imaging after dipyridamole infusion: diagnostic utility in detecting stenoses and relationship to regional wall motion. Circulation 1982;66:649-56.
10. Boucher CA, Brewster DC, Darling RC, Okada RD, Strauss HW, Pohost GM: Determination of cardiac risc by dipyridamole-thallium imaging before peripheral vascular surgery. N Engl J Med 1985;312:389-94.
11. Leppo JA, O’Brien J, Rothendler JA, Getchell JD, Lee VW: Dipyridamole-thallium -201 scintigraphy in the prediction of future cardiac events after acute myocardial infarction. N Engl J Med 1984;310:1014-18.
12. Leppo J, Plaja J; Gionet M, Tumolo J, Paraskos JA, Cutler BS: Noninvasive evaluation of cardiac risc before elective vascular surgery. J Am Coll Cardiol 1987;9:269-76.
13. Verani MS: Pharmacologic stress testing and other alternative techniques in the diagnosis of coronary artery disease. In: Iskandrian AE, Verani MS; eds: Nuclear Cardiac Imaging. 3/ed; Oxford University Pres 2003:164-90.
14. Cosmai EM, Heller GV: The clinical importance of electrocardiographic changes during pharmacologic stress testing with radionuclide myocardial perfusion imaging. J Nucl Cardiol 2005;12:466-72.
15. Marshall ES, Raichlen JS, Kim SM, Intenzo CM, Sawyer DT, Brody EA, et al. Prognostic significance of ST-segment depression during adenozine perfusion imaging. Am Heart J; 1995;130:58-66.
16. Verani MS, Mahmarian JS, Hixson JB, Boyce TM, Staudacher RA: Diagnosis of coronary artery disease by controlled coronary vasodilation with adenosine and thallium-201 scintigraphy in patients unable to exercise. Circulation 1990;82:80-7.
17. Nguyen T, Heo J, Ogilby D, Iskandrian AS: Single-photon emission computed tomography with thallium-201 during adenosine-induced coronary hyperemia: correlation with coronary arteriography, exercise thallium imaging, and two-dimensional echocardiography. J Am Coll Cardiol 1990;16:1375-83.
18. Iskandrian AS, Heo J, NguyenT, Beer SG, Cave V, Ogilby JD, et al. Assessment of coronary artery disease using SPECT with thallium- 201 during adenosine induced coronary hiperemia. Am J Cardiol 1991;67:1190-4.
19. Gupta NC, Esterbrooks DJ, Hilleman DE, Mohiuddin SM. Comparison of adenosine and exercise thallium-201 SPECT myocardial perfusion imaging. J Am Coll Cardiol 1992; 19:248-57.
20. Committee on nuclear cardiology: Imaging guidelines for nuclear cardiology procedures. J Nuc Cardiol 1999;6;G49-G84.
21. Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, et al: ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002;40;1531-40.
22. Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA, et al: Committee on coronary angiography: ACC/AHA Guidelines for coronary angigraphy. J Am Coll Cardiol 1999;33;1756-824.
23. Heller GV. Tracer selection with different stress modalities based on tracer kinetics. J Nucl Cardiol 1996;3S15-21.
24. Iskandrian AS, Verani MS, Heo J: Pharmacologic stress testing: Mechanism of action, hemodynamic responses, and results in detection of coronary artery disease. J Nucl Cardiol 1994;1:94-111.
25. Lette J, Tatum JL, Fraser S, Miller DD, Waters DD, Heller G, et al: Safety of dipyridamole testing in 73806 patients: The multicenter dipyridamole safety study. J Nucl Cardiol 1995;2;3-17.
26. Nishimura S, Kimball KT, Mahmarian JJ, Verani MS: Angiographic and hemodynamic determinants of myocardial ischemia during adenosine thallium-201 scintigraphy in coronary artery disease: Circulation 1993;87:1211-9.
27. Albro PC, Gould KL, Westcott RJ, Hamilton GW, Ritchie JL, Williams DL: Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacological coronary vasodilation. III. Clinical trial. Am J Cardiol; 1978;41:751-60.
28. Chambers CE, Brown KA: Dipyridamole-induced ST segment depression during thallium- 201 imaging in patients with coronary artery disease: Angiographic and hemodynamic determinants. J Am Coll Cardiol 1988;12:37-41.
29. Ranhosky A, Kempthorne-Rawson J: Intravenous Dipyridamole Thallium Imaging Study Group: The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Circulation 1990;81:1205-9.
30. Abreu A, Mahmarian JJ, Nishimura S, Boyce TM, Verani MS: Tolerance and safety of pharmacologic coronary vasodilation with adenosine in association with thallium-201 scintigraphy in patients with suspected coronary artery disease. J Am Coll Cardiol; 1991;18:730-5.
31. Nishimura S, Mahmarian JJ, Boyce TM, Verani MS: Quantitative thallium-201 single-photon emission computed tomography during maximal pharmacologic coronary vasodilation with adenosine for assessing coronary artery disease. J Am Coll Cardiol 1991;18:736-45.
32. Chalea WA, Cruz SH, Moraes AP, Soares Junior J, Giorgi MC, Izaki M, et al: Scintigraphy of miyocardial perfusion combined with pharmacologic stress with dipyridamole. Arq Bras Cardiol 1993;61:207-11.
33. Iskandrian AS, Heo J, LemlekJ, Ogilby JD, Untreker WJ, Iskandrian B, et al: Identification of high risk patients with left main and three vessel coronary artery disease by adenosine SPECT thallium imaging. Am Heart J 1993;125:1130-5.
34. Cortigiani L, Lombardi M, Michelassi C, Paolini EA, Nannini E: Significance of myocardial ischemic electrocardiographic changes during dipyridamole stress echocardiography. Am J Cardiol 1998;82:1008-12.
35. Homma S, Callahan RJ, Amer B, McKusick KA, Strauss HW, Okada RD, et al: Usefulness of oral dipyridamole suspension for stress thallium imaging without exercise in the detection of coronary artery disease. Am J Cardiol 1986;57:503-8.
36. Beller GA: Physiologic effects of intravenously administered dipyridamole or adenosine. In: Beller GA: Current problems in cardiology. Mosby-Year Book Inc;1991:504-5.
37. Gould KL: Pharmacologic intervention as an alternative to exercise stress. Sem Nucl Med 1987;17:121-30.
38. Homma S, Gilliland Y, Guiney TE, Strauss HW, Boucher CA: Safety of intravenous dipyridamole for stress testing with thallium imaging. Am J Cardiol 1987;59:152-4.
39. Feldman RL, Nichols WW, Pepine CJ, Conti CR: Acute effect of intravenous dipyridamole on regional coronary hemodynamics and metabolism. Circulation 1981;64:333-44.
40. Rosseel M, Dendale P, De Sadeleer C, Schoors D, Block P, Franken PR: Dipyridamole- induced angina pectoris during sestamibi stress test in patients with significant coronary artery disease: clinical, angiographic, and nuclear determinants. Angiology 1997;48:301-7.
41. Iskandrian AS, Heo J: Myocardial ischemia during pharmacologic coronary vasodilatation: a concept in search of definition. Cath Cardiovasc Diagn 1989;18:65-6.
42. Rugge PF, Wall EE, Bruschke AVG: New developments in pharmacologic stress imaging. Am Heart J 1992:468-85.
43. Beller GA: Dipyridamole thallium 201 imaging: How safe is it?[Editorial]. Circulation 1990;81:1425-7.
44. Iskandrian AS: Myocardial ischemia during pharmacological stress testing. [Editorial]. Circulation 1993;87:1415-7.
45. Marshall ES, Raichlen JS, Tighe DA, Paul JJ, Bruninger KM, Chung EK: ST-segment depression during adenosine infusion as a predictor of myocardial ischemia. Am Heart J 1994;127:305-11.
46. Zhu YY, Lee W, Botvinick E, Dae M, Chatterjee K, Danforth J, et al: The clinical and pathophysiologic implications of pain, ST abnormalities, and scintigraphic changes induced during dipyridamole infusion: their relationships to the peripheral hemodynamic response. Am Heart J 1988;116:1071-80.
47. Villanueva FS, Smith WH, Watson DD, Beller GA: ST-segment depression during dipyridamole infusion, and its clinical, scintigraphic and hemodynamic correlates. Am J Cardiol 1992,69:445-8.
48. Laarman GJ, Verzijlbergen JK, Ascoop CA: Ischemic ST-segment changes after dipyridamole infusion. Int J Cardiol 1987;14;384-6.
49. Vitola JV, Brambatti JC, Caligaris F, Lesse CR, Nogueira PR, Joaquim AI, et al: Exercise supplementation to dipyridamole prevents hypotension, improves electrocardiogram sensitivity, and increases heart-to-liver activity ratio on Tc-99m sestamibi imaging. J Nucl Cardiol 2001;8:652-9.
50. Lattanzi F, Picano E, Bolognese L, Piccinino C, Sarosso G, Orlandini A, et al: Inhibition of dipyridamole-induced ischemia by antianginal therapy in humans: Correlation with exercise electrocardiography. Circulation 1991;83: 1256-62.
51. Casale PN, Guiney TE, Strauss W, Boucher CA: Simultaneous low level treadmill exercise and intravenous dipyridamole stress thallium imaging. Am J Cardiol 1988;62:799-802.
52. Sketch MH, Mooss AN, Butler ML, Nair CK, Mohiuddin SM: Digoxin-induced positive exercise tests: their clinical and prognostic significance. Am J Cardiol 1981;48:655-9.
53. LeWinter MM, Crawford MH, O'Rourke RA, Karliner JS: The effects of oral propranolol, digoxin and combination therapy on the resting and exercise electrocardiogram. Am Heart J 1977;93:202-9.
54. Sundqvist K, Atterhög JH, Jogestrand T: Effect of digoxin on the electrocardiogram at rest and during exercise in healthy subjects. Am J Cardiol 1986;57(8):661-5.
55. Kayaalp O: Rasyonel tedavi yönünden tıbbi farmakoloji. Feryal Matbaacılık; 4. Baskı, 2. Cilt 1353-4.
56. Katzung BG. Basic and clinical pharmacology. Appleton&Lange Publishers; 6th ed. 1995.
57. Whinnery JE, Froelicher VF, Stuart AJ: The electrocardiographic response to maximal treadmill exercise in asymptomatic men with left bundle branch block. Am Heart J 1997;94:316.
58. Whinnery JE, Froelicher VF Jr, Longo MR Jr, Triebwasser JH: The electrocardiographic response to maximal treadmill exercise in asymptomatic men with right branch bundle block. Chest 1977;71:335-40.
59. Vashist A,Victoria A, Blum S, Bella J, Heller EN. Do electrocardiographic changes with adenosine myocardial perfusion imaging predict ischemia in patients with left ventricular hypertrophy? Nucl Med Commun 2004;25: 553-6.

Turkish Journal of Nuclear Medicine (. Molecular Imaging and Radionuclide Therapy)-Cover

ISSN: 1304-1495
Yayın Aralığı: Yılda 4 Sayı
Başlangıç: 1992
Yayıncı: Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.